Patents by Inventor Pan Zheng

Pan Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10618960
    Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: April 14, 2020
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • Publication number: 20190307841
    Abstract: The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 10, 2019
    Applicant: OncoImmune, Inc.
    Inventors: Yang LIU, Pan Zheng
  • Publication number: 20190263889
    Abstract: This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.
    Type: Application
    Filed: September 19, 2017
    Publication date: August 29, 2019
    Applicants: ONCOIMMUNE, INC., CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Wei WU, Xuexiang DU, Mingyue LIU, Fei TANG
  • Publication number: 20190255140
    Abstract: The present invention relates to treating, a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIT inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIE inhibitor.
    Type: Application
    Filed: March 6, 2019
    Publication date: August 22, 2019
    Applicant: OncoImmune, Inc.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Patent number: 10369197
    Abstract: The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: August 6, 2019
    Assignee: OncoImmune, Inc.
    Inventors: Yang Liu, Pan Zheng
  • Publication number: 20190127468
    Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: December 14, 2016
    Publication date: May 2, 2019
    Applicant: ONCOIMMUNE, INC.
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • Publication number: 20190119353
    Abstract: Chimeric fusion proteins and polynucleotides encoding the chimeric fusion proteins are provided for the treatment of proliferative disorders, automimmune diseases and alloimmune responses. The chimeric fusion proteins comprise a CD24 extracellular domain, an EBV-induced 3 (EBI3) polypeptide subunit, and a p28 IL-27 polypeptide subunit, wherein the EBB polypeptide and the p28 IL-27 polypeptide subunit are covalently joined by a flexible peptide linker.
    Type: Application
    Filed: November 5, 2015
    Publication date: April 25, 2019
    Inventors: Xue-Feng BAI, Yang LIU, Pan ZHENG, Jin-Qing LIU
  • Publication number: 20190038716
    Abstract: This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.
    Type: Application
    Filed: February 2, 2017
    Publication date: February 7, 2019
    Applicant: ONCOIMMUNE, INC.
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • Publication number: 20190016783
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: August 16, 2018
    Publication date: January 17, 2019
    Applicant: ONCOLMMUNE, INC.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Publication number: 20180344642
    Abstract: A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1? and/or HIF-2? includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.
    Type: Application
    Filed: November 9, 2016
    Publication date: December 6, 2018
    Inventors: Yang LIU, Yin WANG, Yan LIU, Christopher BAILEY, Pan ZHENG
  • Publication number: 20180177841
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Application
    Filed: December 12, 2017
    Publication date: June 28, 2018
    Applicant: OncoImmune, Inc.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Publication number: 20180110828
    Abstract: The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.
    Type: Application
    Filed: May 6, 2016
    Publication date: April 26, 2018
    Applicant: OncoImmune, Inc.
    Inventors: Yang LIU, Pan ZHENG
  • Patent number: 9877998
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: January 30, 2018
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Publication number: 20170239315
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Application
    Filed: March 3, 2017
    Publication date: August 24, 2017
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Publication number: 20170233453
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: February 21, 2017
    Publication date: August 17, 2017
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Patent number: 9623070
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: April 18, 2017
    Assignee: Oncolmmune, Inc.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Patent number: 9611309
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: April 4, 2017
    Assignee: Oncolmmune, Inc.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Publication number: 20170035832
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Application
    Filed: August 11, 2016
    Publication date: February 9, 2017
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Patent number: 9427413
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: August 30, 2016
    Assignee: OncoImmune, Inc.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Publication number: 20150239953
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: October 21, 2014
    Publication date: August 27, 2015
    Applicant: Oncolmmune, Inc.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng